---
title: "Bio-Techne: Competitors"
description: "Bio-Techne compared with companies that share its SEC industry classification: revenue, growth and margins from SEC filings, and how the peer group is chosen."
canonical: https://www.getswoopr.com/stocks/companies/bio-techne/competitors/
source: "Swoopr Investment: https://www.getswoopr.com"
---

# Bio-Techne: Competitors & Industry Structure



## Direct Answer

SEC EDGAR classifies Bio-Techne under SIC code 2836 (Biological Products, (No Diagnostic Substances)). Among Swoopr's S&P 500 Equal Weight companies, 86 others share that classification; by latest reported revenue, Bio-Techne ranks 8 of 87. A filing classification is a starting point: a company's real competitors depend on its segments, which its 10-K describes.

## How Does Bio-Techne Compare With Its Peers?

| Company | Revenue (latest FY) | Revenue growth | Operating margin | Net margin |
| --- | --- | --- | --- | --- |
| [Amgen (AMGN)](https://www.getswoopr.com/stocks/companies/amgen/) | $36.8 billion FY2025 | 10.0% | 24.7% | 21.0% |
| [Gilead Sciences (GILD)](https://www.getswoopr.com/stocks/companies/gilead-sciences/) | $29.4 billion FY2025 | 2.4% | 34.0% | 28.9% |
| [Biogen (BIIB)](https://www.getswoopr.com/stocks/companies/biogen/) | $9.9 billion FY2025 | 2.2% | n/a | 13.1% |
| [Neurocrine Biosciences Inc. (NBIX)](https://www.getswoopr.com/stocks/companies/neurocrine-biosciences-inc/) | $2.9 billion FY2025 | 21.4% | 21.6% | 16.7% |
| [Exelixis Inc. (EXEL)](https://www.getswoopr.com/stocks/companies/exelixis-inc/) | $2.3 billion FY2025 | 7.0% | 37.6% | 33.7% |
| [Moderna (MRNA)](https://www.getswoopr.com/stocks/companies/moderna/) | $1.9 billion FY2025 | -39.9% | -158.1% | -145.2% |
| [Halozyme Therapeutics Inc. (HALO)](https://www.getswoopr.com/stocks/companies/halozyme-therapeutics-inc/) | $1.4 billion FY2025 | 37.6% | 33.6% | 22.7% |
| **Bio-Techne (TECH)** | $1.2 billion FY2025 | 5.2% | 8.4% | 6.0% |
| [Novavax Inc. (NVAX)](https://www.getswoopr.com/stocks/companies/novavax-inc/) | $1.1 billion FY2025 | 64.7% | 40.3% | 39.2% |
| [BioCryst Pharmaceuticals Inc. (BCRX)](https://www.getswoopr.com/stocks/companies/biocryst-pharmaceuticals-inc/) | $875 million FY2025 | 94.1% | 39.0% | 30.2% |
| [Repligen Corporation (RGEN)](https://www.getswoopr.com/stocks/companies/repligen-corporation/) | $738 million FY2025 | 16.4% | 7.5% | 6.6% |
| [Tarsus Pharmaceuticals Inc. (TARS)](https://www.getswoopr.com/stocks/companies/tarsus-pharmaceuticals-inc/) | $451 million FY2025 | 146.7% | -15.7% | -14.6% |
| [Krystal Biotech Inc. (KRYS)](https://www.getswoopr.com/stocks/companies/krystal-biotech-inc/) | $389 million FY2025 | 33.9% | 41.5% | 52.6% |
| [Twist Bioscience Corporation (TWST)](https://www.getswoopr.com/stocks/companies/twist-bioscience-corporation/) | $377 million FY2025 | 20.3% | -36.2% | -20.6% |
| [Adaptive Biotechnologies Corporation (ADPT)](https://www.getswoopr.com/stocks/companies/adaptive-biotechnologies-corporation/) | $277 million FY2025 | 54.8% | -20.6% | -21.5% |
| [Iovance Biotherapeutics Inc. (IOVA)](https://www.getswoopr.com/stocks/companies/iovance-biotherapeutics-inc/) | $264 million FY2025 | 60.6% | -153.1% | -148.4% |
| [REGENXBIO Inc. (RGNX)](https://www.getswoopr.com/stocks/companies/regenxbio-inc/) | $170 million FY2025 | 104.5% | -94.6% | -113.8% |
| [Ginkgo Bioworks Holdings Inc. (DNA)](https://www.getswoopr.com/stocks/companies/ginkgo-bioworks-holdings-inc/) | $170 million FY2025 | -25.1% | -185.3% | -0.2% |
| [Maze Therapeutics Inc. (MAZE)](https://www.getswoopr.com/stocks/companies/maze-therapeutics-inc/) | $168 million FY2024 | n/a | 34.4% | 31.2% |
| [Beam Therapeutics Inc. (BEAM)](https://www.getswoopr.com/stocks/companies/beam-therapeutics-inc/) | $140 million FY2025 | 120.0% | -274.6% | -57.2% |
| [Monte Rosa Therapeutics Inc. (GLUE)](https://www.getswoopr.com/stocks/companies/monte-rosa-therapeutics-inc/) | $124 million FY2025 | 63.5% | -43.8% | -31.2% |
| [Atara Biotherapeutics Inc. (ATRA)](https://www.getswoopr.com/stocks/companies/atara-biotherapeutics-inc/) | $121 million FY2025 | -6.3% | 29.7% | 27.1% |
| [Agenus Inc. (AGEN)](https://www.getswoopr.com/stocks/companies/agenus-inc/) | $114 million FY2025 | 10.4% | -17.7% | -2.7% |
| [ImmunityBio Inc. (IBRX)](https://www.getswoopr.com/stocks/companies/immunitybio-inc/) | $113 million FY2025 | 668.3% | -226.0% | -310.3% |
| [Century Therapeutics Inc. (IPSC)](https://www.getswoopr.com/stocks/companies/century-therapeutics-inc/) | $109 million FY2025 | 1556.8% | -15.8% | -8.8% |
| [Sutro Biopharma Inc. (STRO)](https://www.getswoopr.com/stocks/companies/sutro-biopharma-inc/) | $102 million FY2025 | 65.2% | -154.5% | -186.4% |
| [4D Molecular Therapeutics Inc. (FDMT)](https://www.getswoopr.com/stocks/companies/4d-molecular-therapeutics-inc/) | $85 million FY2025 | 230194.6% | -187.2% | -164.4% |
| [MeiraGTx Holdings plc (MGTX)](https://www.getswoopr.com/stocks/companies/meiragtx-holdings-plc/) | $81 million FY2025 | 144.6% | -130.2% | -140.3% |
| [Recursion Pharmaceuticals Inc. (RXRX)](https://www.getswoopr.com/stocks/companies/recursion-pharmaceuticals-inc/) | $75 million FY2025 | 26.9% | -867.9% | -863.4% |
| [Black Diamond Therapeutics Inc. (BDTX)](https://www.getswoopr.com/stocks/companies/black-diamond-therapeutics-inc/) | $70 million FY2025 | n/a | 17.9% | 31952.9% |
| [Champions Oncology Inc. (CSBR)](https://www.getswoopr.com/stocks/companies/champions-oncology-inc/) | $59 million FY2026 | 4.4% | -1.9% | -0.0% |
| [Invivyd Inc. (IVVD)](https://www.getswoopr.com/stocks/companies/invivyd-inc/) | $53 million FY2025 | 110.5% | -104.0% | -98.2% |
| [BioStem Technologies Inc. (BSEM)](https://www.getswoopr.com/stocks/companies/biostem-technologies-inc/) | $47 million FY2025 | -31.8% | -1.5% | -13.9% |
| [Fennec Pharmaceuticals Inc. (FENC)](https://www.getswoopr.com/stocks/companies/fennec-pharmaceuticals-inc/) | $45 million FY2025 | -6.1% | -14.1% | -21820.3% |
| [Coherus Oncology Inc. (CHRS)](https://www.getswoopr.com/stocks/companies/coherus-oncology-inc/) | $42 million FY2025 | 59.8% | -429.5% | 398.4% |
| [Editas Medicine Inc. (EDIT)](https://www.getswoopr.com/stocks/companies/editas-medicine-inc/) | $41 million FY2025 | 25.4% | -394.9% | -395.0% |
| [Voyager Therapeutics Inc. (VYGR)](https://www.getswoopr.com/stocks/companies/voyager-therapeutics-inc/) | $40 million FY2025 | -49.5% | -326.6% | -296.5% |
| [Kymera Therapeutics Inc. (KYMR)](https://www.getswoopr.com/stocks/companies/kymera-therapeutics-inc/) | $39 million FY2025 | -16.7% | -891.1% | 794.0% |
| [C4 Therapeutics Inc. (CCCC)](https://www.getswoopr.com/stocks/companies/c4-therapeutics-inc/) | $36 million FY2025 | 1.0% | -320.5% | -292.1% |
| [Precision BioSciences Inc. (DTIL)](https://www.getswoopr.com/stocks/companies/precision-biosciences-inc/) | $34 million FY2025 | -50.1% | -152.2% | -133.4% |
| [Scilex Holding Company (SCLX)](https://www.getswoopr.com/stocks/companies/scilex-holding-company/) | $30 million FY2025 | -46.5% | -1143.7% | -1236.4% |
| [Metagenomi Therapeutics Inc. (MGX)](https://www.getswoopr.com/stocks/companies/metagenomi-therapeutics-inc/) | $25 million FY2025 | -51.8% | -380.9% | -348.5% |
| [Alector Inc. (ALEC)](https://www.getswoopr.com/stocks/companies/alector-inc/) | $21 million FY2025 | -79.1% | -741.3% | -679.5% |
| [LENZ Therapeutics Inc. (LENZ)](https://www.getswoopr.com/stocks/companies/lenz-therapeutics-inc/) | $19 million FY2025 | n/a | -477.5% | -430.3% |
| [Relay Therapeutics Inc. (RLAY)](https://www.getswoopr.com/stocks/companies/relay-therapeutics-inc/) | $15 million FY2025 | 53.4% | -1971.6% | -1800.6% |
| [Lineage Cell Therapeutics Inc. (LCTX)](https://www.getswoopr.com/stocks/companies/lineage-cell-therapeutics-inc/) | $15 million FY2025 | 53.2% | -251.6% | -436.5% |
| [Elutia Inc. (ELUT)](https://www.getswoopr.com/stocks/companies/elutia-inc/) | $12 million FY2025 | -15.0% | -218.9% | 434.2% |
| [Caribou Biosciences Inc. (CRBU)](https://www.getswoopr.com/stocks/companies/caribou-biosciences-inc/) | $11 million FY2025 | 11.7% | -1329.4% | -1327.4% |
| [TScan Therapeutics Inc. (TCRX)](https://www.getswoopr.com/stocks/companies/tscan-therapeutics-inc/) | $10 million FY2025 | 266.7% | -1315.4% | -1256.8% |
| [Taysha Gene Therapies Inc. (TSHA)](https://www.getswoopr.com/stocks/companies/taysha-gene-therapies-inc/) | $10 million FY2025 | 17.3% | -1130.6% | -1115.3% |
| [Curis Inc. (CRIS)](https://www.getswoopr.com/stocks/companies/curis-inc/) | $9 million FY2025 | -13.4% | -60.5% | -80.3% |
| [Solid Biosciences Inc. (SLDB)](https://www.getswoopr.com/stocks/companies/solid-biosciences-inc/) | $8 million FY2022 | n/a | -1315.2% | -1062.3% |
| [Fate Therapeutics Inc. (FATE)](https://www.getswoopr.com/stocks/companies/fate-therapeutics-inc/) | $7 million FY2025 | -51.2% | -2222.4% | -2051.1% |
| [X4 Pharmaceuticals Inc. (XFOR)](https://www.getswoopr.com/stocks/companies/x4-pharmaceuticals-inc/) | $7 million FY2025 | 150.0% | -1336.7% | -1218.4% |
| [Prime Medicine Inc. (PRME)](https://www.getswoopr.com/stocks/companies/prime-medicine-inc/) | $5 million FY2025 | 55.3% | -4498.1% | -4342.4% |
| [Ocugen Inc. (OCGN)](https://www.getswoopr.com/stocks/companies/ocugen-inc/) | $4 million FY2025 | 8.8% | -1425.7% | -1540.9% |
| [CG Oncology Inc. (CGON)](https://www.getswoopr.com/stocks/companies/cg-oncology-inc/) | $4 million FY2025 | 254.7% | -4722.1% | -3985.1% |
| [Surrozen Inc. (SRZN)](https://www.getswoopr.com/stocks/companies/surrozen-inc/) | $3 million FY2025 | -67.4% | -1210.6% | -6960.8% |
| [Dyadic International Inc. (DYAI)](https://www.getswoopr.com/stocks/companies/dyadic-international-inc/) | $3 million FY2025 | -11.6% | -232.8% | -238.3% |
| [Aligos Therapeutics Inc. (ALGS)](https://www.getswoopr.com/stocks/companies/aligos-therapeutics-inc/) | $2 million FY2025 | -39.5% | -4024.9% | -1106.7% |
| [Humacyte Inc. (HUMA)](https://www.getswoopr.com/stocks/companies/humacyte-inc/) | $2 million FY2025 | n/a | -5306.0% | -2003.6% |
| [Outlook Therapeutics Inc. (OTLK)](https://www.getswoopr.com/stocks/companies/outlook-therapeutics-inc/) | $1 million FY2025 | n/a | -4744.3% | -4416.2% |
| [Inhibrx Biosciences Inc. (INBX)](https://www.getswoopr.com/stocks/companies/inhibrx-biosciences-inc/) | $1 million FY2025 | 550.0% | -10386.5% | -10773.5% |
| [ProKidney Corp. (PROK)](https://www.getswoopr.com/stocks/companies/prokidney-corp/) | $893,000 FY2025 | 1075.0% | -18477.8% | -7725.2% |
| [ImageneBio Inc. (IMA)](https://www.getswoopr.com/stocks/companies/imagenebio-inc/) | $800,000 FY2025 | -77.1% | -6056.4% | -5668.6% |
| [Lexeo Therapeutics Inc. (LXEO)](https://www.getswoopr.com/stocks/companies/lexeo-therapeutics-inc/) | $654,000 FY2022 | n/a | -9252.1% | -9063.8% |
| [Cardiff Oncology Inc. (CRDF)](https://www.getswoopr.com/stocks/companies/cardiff-oncology-inc/) | $593,000 FY2025 | -13.2% | -8256.3% | -7.7% |
| [aTyr Pharma Inc. (ATYR)](https://www.getswoopr.com/stocks/companies/atyr-pharma-inc/) | $190,000 FY2025 | -19.1% | -40856.3% | -39009.5% |
| [VivoSim Labs Inc. (VIVS)](https://www.getswoopr.com/stocks/companies/vivosim-labs-inc/) | $131,000 FY2026 | -9.0% | -8768.7% | -10567.2% |
| [Candel Therapeutics Inc. (CADL)](https://www.getswoopr.com/stocks/companies/candel-therapeutics-inc/) | $125,000 FY2022 | n/a | -27777.6% | -15035.2% |
| [eXoZymes Inc. (EXOZ)](https://www.getswoopr.com/stocks/companies/exozymes-inc/) | $70,069 FY2023 | n/a | -2563.5% | -2909.1% |
| [INmune Bio Inc. (INMB)](https://www.getswoopr.com/stocks/companies/inmune-bio-inc/) | $50,000 FY2025 | 257.1% | -94766.0% | -92000.0% |
| [Senti Biosciences Holdings Inc. (SNTI)](https://www.getswoopr.com/stocks/companies/senti-biosciences-holdings-inc/) | $22,000 FY2025 | n/a | -312631.8% | -279263.6% |
| [Creative Medical Technology Holdings Inc. (CELZ)](https://www.getswoopr.com/stocks/companies/creative-medical-technology-holdings-inc/) | $6,000 FY2025 | -45.5% | -102380.2% | -99916.8% |
| [Allogene Therapeutics Inc. (ALLO)](https://www.getswoopr.com/stocks/companies/allogene-therapeutics-inc/) | $0 FY2025 | -100.0% | n/a | n/a |
| [Artiva Biotherapeutics Inc. (ARTV)](https://www.getswoopr.com/stocks/companies/artiva-biotherapeutics-inc/) | $0 FY2025 | -100.0% | n/a | n/a |
| [BioCardia Inc. (BCDA)](https://www.getswoopr.com/stocks/companies/biocardia-inc/) | $0 FY2025 | -100.0% | n/a | n/a |
| [Compass Therapeutics Inc. (CMPX)](https://www.getswoopr.com/stocks/companies/compass-therapeutics-inc/) | $0 FY2025 | -100.0% | n/a | n/a |
| [Cullinan Therapeutics Inc. (CGEM)](https://www.getswoopr.com/stocks/companies/cullinan-therapeutics-inc/) | $0 FY2022 | n/a | n/a | n/a |
| [Denali Therapeutics Inc. (DNLI)](https://www.getswoopr.com/stocks/companies/denali-therapeutics-inc/) | $0 FY2025 | n/a | n/a | n/a |
| [Eloxx Pharmaceuticals Inc. (ELOX)](https://www.getswoopr.com/stocks/companies/eloxx-pharmaceuticals-inc/) | $0 FY2025 | -100.0% | n/a | n/a |
| [Inhibikase Therapeutics Inc. (IKT)](https://www.getswoopr.com/stocks/companies/inhibikase-therapeutics-inc/) | $0 FY2024 | -100.0% | n/a | n/a |
| [Palisade Bio Inc. (PALI)](https://www.getswoopr.com/stocks/companies/palisade-bio-inc/) | $0 FY2025 | n/a | n/a | n/a |
| [PharmaCyte Biotech Inc. (PMCB)](https://www.getswoopr.com/stocks/companies/pharmacyte-biotech-inc/) | $0 FY2026 | n/a | n/a | n/a |
| [Revolution Medicines Inc. (RVMD)](https://www.getswoopr.com/stocks/companies/revolution-medicines-inc/) | $0 FY2025 | n/a | n/a | n/a |
| [SAB Biotherapeutics Inc. (SABS)](https://www.getswoopr.com/stocks/companies/sab-biotherapeutics-inc/) | $0 FY2025 | -100.0% | n/a | n/a |
| [Scholar Rock Holding Corporation (SRRK)](https://www.getswoopr.com/stocks/companies/scholar-rock-holding-corporation/) | $0 FY2025 | n/a | n/a | n/a |

Revenue growth compares each company's latest fiscal year with the one before. Fiscal years do not always end on the same date, so treat close comparisons with care.

![Bar chart of operating margin for Bio-Techne and 7 peers: Amgen (AMGN) 24.7%, Gilead Sciences (GILD) 34.0%, Neurocrine Biosciences Inc. (NBIX) 21.6%, Exelixis Inc. (EXEL) 37.6%, Moderna (MRNA) -158.1%, Halozyme Therapeutics Inc. (HALO) 33.6%, Bio-Techne (TECH) 8.4%, Novavax Inc. (NVAX) 40.3%.](https://www.getswoopr.com/images/charts/bio-techne-competitors-peer-margins.webp)
*Operating margin of Bio-Techne against companies sharing its SEC industry classification, from the table above. Select the chart to open it full size.*

## How Does Bio-Techne Rank Among All SEC Filers in Its Industry Code?

74 companies with annual reports in Swoopr's SEC dataset share SIC code 2836 (Biological Products, (No Diagnostic Substances)), a wider group than the S&P 500 Equal Weight companies above. Ranks run from 1 (highest) and use each company's latest fiscal year, in U.S. dollars.

| Measure | Bio-Techne | Median of filers | Rank |
| --- | --- | --- | --- |
| Revenue | $1.2 billion | $40 million | 8 of 74 |
| Revenue growth | 5.2% | 14.0% | 38 of 64 |
| Operating margin | 8.4% | -274.6% | 12 of 73 |
| Net margin | 6.0% | -212.3% | 17 of 74 |

A SIC code reflects the filer's main business as the SEC records it, so the group mixes companies of very different size; the median is a better guide than the average, and a rank near the top by revenue says nothing about quality.

## Where These Numbers Come From

Every figure on this page is a value Bio-Techne reported in its own SEC filings, read from the SEC's XBRL data (accession 0001104659-26-100322 for fiscal year 2025). Ratios are computed from those reported values. Figures were retrieved on October 12, 2026; a later amendment or a new annual report can change them, and the filing itself always takes precedence over this summary.

Each fiscal year is labeled by the calendar year in which it ended, so a company that names the same period differently in its own filings (many retailers whose year ends in January) may use another label. A year is left out of the table when the SEC data set holds no value for it. A figure shown as "Not reported" means the company did not file a value under the standard tag Swoopr reads, not that the amount was zero. This page is educational and describes reported history only; it is not a forecast or a recommendation.

## Frequently Asked Questions

### Who are Bio-Techne's competitors?

Companies sharing Bio-Techne's SEC classification (SIC code 2836 (Biological Products, (No Diagnostic Substances))) include Amgen (AMGN), Gilead Sciences (GILD), Biogen (BIIB), Neurocrine Biosciences Inc. (NBIX), Exelixis Inc. (EXEL). Its 10-K names the competitors it considers most relevant.

### How does Bio-Techne compare with its peers on margins?

Bio-Techne's fiscal 2025 operating margin was 8.4%, against a peer median of -297.6%.

### How are these peers chosen?

By the SEC Standard Industrial Classification code each company files under, within Swoopr's S&P 500 Equal Weight company set, falling back to the two-digit major group when fewer than two companies share the exact code. Classification codes are broad, so read the peer list as a screen, not a verdict.

### How does Bio-Techne rank among all companies in its SEC industry?

Among 74 SEC filers under SIC code 2836, Bio-Techne ranks 8 by latest revenue, and 12 of 73 by operating margin (8.4% against a median of -274.6%).

## References

- [SEC EDGAR: BIO-TECHNE Corp Form 10-K filed August 24, 2026](https://www.sec.gov/Archives/edgar/data/842023/000110465926100322/tech-20260630x10k.htm)
- [SEC EDGAR: BIO-TECHNE Corp annual and quarterly filings](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=842023&type=10-K)
- [SEC: EDGAR application programming interfaces (XBRL frames and submissions data)](https://www.sec.gov/search-filings/edgar-application-programming-interfaces)

## Related Pages

- [Bio-Techne company dossier](https://www.getswoopr.com/stocks/companies/bio-techne/)
- [Bio-Techne financial metrics](https://www.getswoopr.com/stocks/companies/bio-techne/metrics/)
- [Bio-Techne financial risk indicators](https://www.getswoopr.com/stocks/companies/bio-techne/risks/)
- [Bio-Techne peer comparison](https://www.getswoopr.com/stocks/companies/bio-techne/competitors/)
- [Bio-Techne business model and revenue mix](https://www.getswoopr.com/stocks/companies/bio-techne/business-model/)
- [Fundamental analysis guides](https://www.getswoopr.com/learn/fundamental-analysis/)





**[Swoopr Editorial Team](https://www.getswoopr.com/authors/swoopr-editorial-team/)**



Swoopr's editorial team produces independent investment education content reviewed for accuracy and clarity. We do not provide personalized financial advice. See our [editorial policy](https://www.getswoopr.com/legal/editorial-policy/) and [corrections policy](https://www.getswoopr.com/legal/corrections-policy/).